CAMBRIDGE, Mass., Dec. 9 /PRNewswire-FirstCall/ -- Transkaryotic
Therapies, Inc. (Nasdaq: TKTX) today announced that the company will present
at Wachovia Capital Markets' Ten for '05 Biotechnology Conference being held
at the Ritz Carlton, Central Park in New York on December 16, 2004. The
conference will feature ten companies expected to report pivotal clinical
trial results in 2005. David D. Pendergast, Ph.D., Chief Operating Officer of
TKT, will present an overview of the company's AIM study (Assessment of I2S in
MPS II) at 9:30 a.m. Eastern Standard Time. The AIM study is a pivotal trial
evaluating iduronate-2-sulfatase (I2S), TKT's investigational enzyme
replacement therapy being development for the treatment of Hunter syndrome.
TKT expects top-line results from the AIM study in June 2005, and, if
positive, the company expects to submit applications for marketing approval in
both the United States and Europe in the second half of 2005.
A live audio webcast of this presentation will be available at
http://www.tktx.com on TKT's Investor Information website under the Events
category. A replay will be available for approximately 30 days after the
webcast.
About TKT
Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily
focused on researching, developing and commercializing treatments for rare
diseases caused by protein deficiencies. Within this focus, the company
markets Replagal(TM), an enzyme replacement therapy for Fabry disease, and is
developing treatments for Hunter syndrome and Gaucher disease. In addition to
its focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene-
Activated(R) erythropoietin product for anemia related to kidney disease, in
the European Union. TKT was founded in 1988 and is headquartered in
Cambridge, Massachusetts, with additional operations in Europe, Canada and
South America. Additional information about TKT is available on the company's
website at http://www.tktx.com.
Gene-Activated(R) is a registered trademark and Replagal(TM) is a
trademark of Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of
Sanofi-Aventis SA.
For More Information Contact:
Daniella M. Lutz
Corporate Communications Manager
(617) 349-0205
SOURCE Transkaryotic Therapies, Inc.
 back to top
Related links:
http://www.tktx.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
Company News On-Call:
http://www.prnewswire.com/comp/120657.html
CONTACT:
Daniella M. Lutz, Corporate Communications
Manager of Transkaryotic Therapies, Inc., +1-617-349-0205
|
